IL-1 is an important mediator of innate inflammatory responses and has been shown to contribute to liver injury in a number of etiologies. HIV patients have increased necroinflammation and more rapid fibrosis progression in chronic liver injury compared to non-HIV-infected patients.
INTRODUCTION
As blood enters the liver, predominantly through the portal circulation, it is distributed through the hepatic sinusoids, which are lined by a uniquely fenestrated endothelium interspersed with resident liver macrophages, also known as Kupffer cells (KCs). KCs are long-lived and Abbreviations: MOI, multiplicity of infection; NLRC4, NLR family CARD domian containing; NLRP, nucleotide-binding domain, leucine-rich-containing family, pyrin domain containing abundant, representing 15% to 20% of the total liver cell population. 1, 2 They are responsible for the clearance of translocated bacterial products and thus are tolerant to the proinflammatory effects of LPS under normal physiologic conditions. Therefore, function of these resident liver macrophages is critically important to the liver's ability to clear translocated products, including endogenous TLR ligands that would otherwise promote hepatic inflammation. Furthermore, these cells may serve as the gatekeeper for systemic immune activation, which exists in HIV patients despite antiretroviral therapy. 3 Although no surface marker clearly defines KCs, CD68 has been the most frequently used and therefore is used to define these resident liver macrophages in this study.
Liver disease is one of the leading causes of non-AIDS related mortality in HIV-1-infected patients receiving effective antiretroviral therapy (ART). While earlier initiation of ART and advances in the treatment of viral hepatitis have made a tremendous impact in improving liver outcomes in patients with HIV, there are HIV related alterations that are not restored by ART and may contribute to poor liver outcomes despite antiviral treatments. [4] [5] [6] In HIV infection, CD4 gut depletion and increased gut permeability have been postulated to promote microbial translocation and drive immune activation.
Though plasma LPS levels decrease in patients treated with ART, they never return to the level of HIV-uninfected individuals 5 and microbial translocation is associated with persistent macrophage activation despite viral suppression or CD4 reconstitution. 7 an amplified IL-6 and TNF-proinflammatory response to LPS. 8, 9 Inflammasome activation has been shown to be important in a number of liver diseases ranging from alcoholic steatohepatitis to nonalcoholic steatohepatitis (NASH) to chronic hepatitis C virus (HCV) infection.
One of the main roles of inflammasomes in liver disease is to trigger the inflammatory cytokine IL-1 that synergizes with TLR signaling to amplify responses to LPS. IL-1 then also promotes the recruitment of inflammatory cells to the liver and activates hepatic stellate cells, which contribute to fibrosis. 10 In general, IL-1 production is primed by the sensing of "danger signals," either pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), which then results in the production of mature IL-1 . 11 In the liver, this inflammatory response is mainly mediated by the action of caspase-1, which is usually activated via the inflammasome, most notably by the nucleotide-binding domain leucine-rich-containing family pyrin domain-containing-3 (NLRP3) inflammasome. Although the underlying mechanisms for its contribution remain unclear, an NLRP3 inhibitory assay using a compound MCC950 has confirmed its importance in the caspase-1-IL-1 inflammatory axis. 12, 13 As a critical element in TLR signal transduction, NLRP3 plays an important role in viral-induced IL-1 maturation in macrophages.
However, the pattern of IL-1 maturation in macrophages is different than that in monocytes. ATP, a potassium efflux inducer, is required for IL-1 maturation and secretion from LPS-primed macrophages. 11 Several viral proteins influence IL-1 release. 14 For example, influenza virus NS1 directly interacts with NLRP3 and inhibits NLRP3-mediated IL-1 production. In contrast, Influenza A virus M2 protein can activate NLRP3 and in turn promote IL-1 secretion. 15 NLRP3 also contributes to the induction of the IL-1 response to Newcastle disease virus and HCV infection in THP1-derived macrophages. Furthermore, depletion of NLRP3 can dramatically reduce IL-1 production from the infected cells. 16, 17 Similarly, NLRP3 knockout significantly suppressed the IL-1 response of macrophages to influenza A virus infection in a mouse model. 18 Our previous study has shown that HIV-1 BaL infection induces an amplified inflammatory response through a TLR4-dependent pathway in primary human liver macrophages. However, the impact of HIV-1 BaL infection, and the influence of concomitant microbial translocation, on the IL-1 response of liver macrophages remains incompletely described.
Here we show that HIV-1 infection primes the IL-1 response of CD68 + liver macrophages to LPS through up-regulation of CD14 and 
MATERIALS AND METHODS

Human liver tissue from HIV-1-infected patients
Tissues from HIV-infected patients were utilized for coimmunostaining of IL-1 , CD68, and NLRP3 and Western blot for IL-1 expression and co-immunostaining for CD68 and NLRP3 (Fig. 6 ).
De-identified liver resection specimens from HIV-monoinfected infected patients (n = 7) were provided by Drs. Florman, Schwartz, 
Isolation of CD68+ primary human liver macrophages from liver resections
For all in vitro experiments examining the impact of HIV-1 on liver macrophage biology, primary liver macrophages were isolated from surgical resection specimens (metastatic rectal, colon, and parotid cancer, gall bladder cancer, cholangiocarcinomas, and hepatocellular carcinoma (HCC) (no HCV or hepatitis B virus or underlying cirrhosis) by performing collagenase perfusion and mincing of the liver tissue.
Cells were washed with PBS 4 times, pelleted at 300 × g for 5 min, resuspended in DMEM followed by gradient centrifugation using 25% and 50% Percoll (Pharmacia, Uppsala, Sweden), as described. 19 Liver macrophages were enriched by adherence to tissue culture plates. Cells (2 × 10 6 cells/well in a 24-well plate) were maintained in DMEM media with FBS and after 2 wk in culture, flow cytometry revealed that 82-98% of the cells were liver macrophages. Given the potential heterogeneity of intrahepatic macrophages, CD68 + cells, a common marker for macrophages, were used for subsequent characterization and experimentation.
Tissue immunofluorescence assay
The liver tissue sections were prepared in duplicate for each patient.
Slides were rehydrated and treated for antigen retrieval. Then slides were washed with PBS and incubated with antibodies (please see the Supplemental Table 1 
Immunostaining assay on isolated primary liver macrophages
Macrophages isolated from nontumorous noncirrhotic liver tissue were infected with HIV-1 BaL +/-5nMATP in vitro as described, fixed with 2% paraformaldehyde at room temperature for 20 min. Then the cells were washed with PBS and incubated with first antibodies (please see the Supplemental Table 1 
Flow cytometry analyses
Production and purification of HIV-1 BaL virus
In order to obtain purified HIV-1 BaL 
HIV-1 BaL infection in primary human liver macrophages
To determine replication of HIV-1 BaL in primary liver macrophages, CD68 + liver macrophages were plated at concentration 2 × 10 5 cells/well in 24-well plates and cells were infected at a multiplicity of infection (MOI) of 0.10. The virus was washed off at 3 hr followed by the addition of fresh medium. Media was serially collected and HIV-1 BaL p24 antigen production was measured by ELISA using the SAIC Frederick Kit (National Cancer Institute, Bethesda, MD, USA).
The impact of HIV-1 BaL infection on primary human liver macrophage response to LPS
A total of 72 hr post -IV-1 BaL infection CD68+ liver macrophages were challenged with TLR4 ligand ultra pure LPS (InvivoGen, San Diego, CA, USA; cat. no.: tlrl-ppglps) at a dose of 100 ng/ml for 4 hr, followed by RNA extraction and RT-qPCR at 8 hr posttreatment. Supernatants were collected for ELISA assay at 8 hr post-LPS treatment.
RNA extraction and RT-qPCR
Total RNA was extracted by using RNeasy spin columns (Qiagen, Chatsworth, CA, USA; cat. no.: 74136). After treatment with RNasefree DNase (Qiagen), RT was performed on RNA by using Clontech RNA to cDNA EcoDry kit according to the manufacturer's protocol. RTqPCR was performed on Roche Lightcycle II 480. Reactions were carried out in 10 L by using SYBR Green PCR master mix according to the manufacturer's protocol (Bio-Rad, cat. no.: 1708884, Hercules, CA).
The concentration of primer pairs was 300 nM. All primer sequences are shown in the primer table (Supplemental Table 2 ). All reactions were performed in triplicate. To make comparisons between samples and controls, the CT (cycle threshold, defined as the cycle number at which the fluorescence is above the fixed threshold) values were normalized to the CT of -actin in each sample.
Lactate dehydrogenase (LDH) cytotoxicity assay
Cell culture supernatant was collected from control cells, HIV-1 BaLinfected cells, LPS treated cells, and HIV-1 BaL +LPS treated cells. The cellular toxicity of different treatments was measured using an LDH cytotoxicity assay kit (Thermo Scientific, cat. no.: 88953, Waltham, MA) according to manufacturer's protocols.
ELISA assay
Isolated macrophages were treated with different conditions and then incubated with 5 nM ATP for 8 hr. IL-1 production in the supernatant was collected at indicated time and measured by using human IL-1 ELISA kit (Affymetrix, cat. no.: 88-7261-86, Santa Clara, CA) according to the manufacturer's protocol.
TLR4 signaling blockade
CD68 + liver macrophages isolated as described above were plated in 24-well plates, infected or noninfected with HIV were treated with either LPS (100 ng/ml) and/or TAK-242 (3 M, Invivogen). TAK-242 also known as CLI-095, a small-molecule, has been shown to selectively inhibit TLR4 signaling to suppress LPS-induced inflammation. 20 Eight hours after LPS treatment in the presence or absence of the TLR4 inhibitor, supernatants were collected for IL-1 ELISA.
NLRP3 inflammasome blockade
CD68 + liver macrophages isolated as described above were plated in 24-well plates, infected or noninfected with HIV for 3 hr. MCC950
(Sigma, San Jose, CA, USA; cat. no.: PZ0280-5MG) also known as CRID3, a small-molecule has been shown to selectively inhibit NLRP3 to suppress LPS-induced inflammation. 20 Three hours postinfection, the cells were treated with 1 nM MCC950 for 30 min. Medium was aspirated at indicated time intervals and cells were then cultured with complete medium ±5 nM ATP for 8 hr. Supernatant was collected for IL-1 ELISA assay.
Western blot
Tissue proteins from normal liver and HIV-1 monoinfected liver were purified with T-PER tissue protein extraction reagent (Thermo, cat. 
Statistical analysis
All data were analyzed using SigmaPlot14 software (Sigma). Data were first evaluated for normality using the Shapiro-Wilk test and then were tested for equal variance using the Brown-Forsythe test. Depending on the test results, either mean or median values were calculated.
Comparisons between two groups were made using parametric (Stu- Fig. 2A and B ) that are productively infected by HIV-1 BaL as reflected by p24 ELISA (Fig. 2C) . RT-PCR results also revealed that whereas IL- (Fig. 2E) . Liver macrophages play a major role in the response to microbial products and increased microbial translocation, which has been shown to be increased in HIV-1 infection. 23 vs. 168.70 pg/ml, P < 0.0001) (Fig. 2E) . In addition, LDH cytotoxicity 
RESULTS
HIV infection of liver macrophages in vitro does
HIV-1 BaL induced TLR4 expression is critical for IL-1 response to LPS stimulation in CD68+ macrophages
Because the TLR4 pathway contributes to the inflammatory response of macrophages to microbial products, we compared the expression of CD14 and TLR4 in liver macrophages before and after HIV- pg/ml to 13.589 pg/ml, P = 0.016) was observed in HIV-1 BaL plus LPS treated cells (Fig. 3D) in the presence of the TLR4 inhibitor, suggesting an amplifying effect of HIV-1 BaL infection on IL-1 response to LPS through TLR4.
NLRP3 participates in IL-1 response to LPS stimulation in HIV-1 BaL -infected CD68+macrophages
Caspase 1 inflammasomes have been implicated as important contributors to the activation of IL-1 signaling, and in the liver, NLRP3 liver macrophages (P = 0.046; P = 0.031, respectively) (Fig. 4C) . These results suggest that NLRP3 may contribute to the IL-1 response to HIV-1 BaL infection in KCs.
NLRP3 modulates IL-1 response to HIV-1 BaL infection in liver macrophages
To determine whether NLRP3 modulates the IL-1 response in HIV-1 BaL -infected CD68+ macrophages, we then infected CD68+ macrophages with HIV-1 BaL and examined the expression/ colocalization of IL-1 and NLRP3 expression in CD68+macrophages
as assessed by confocal microscopy (Fig. 5A ). Moreover, a higher level 43.47 pg/ml vs. 10.84 pg/ml, P = 0.013) (Fig. 5C) . Therefore, these results suggest that NLRP3 plays an important role in the modulation of IL-1 response to HIV-1 BaL infection and LPS in liver macrophages.
IL-1 expression is increased in intrahepatic CD68 + macrophages in liver tissue from HIV-infected patients
To assess IL-1 hepatic expression in patients with HIV-1 infection, protein lysates from frozen archived human liver sections from normal After 100 ng/ml LPS challenge, the supernatant was collected 8 hr posttreatment with 5 nM ATP and IL-1 was measured by ELISA (n = 9, duplicate, P = 0.013). Kruskal-Wallis one way analysis with paired t test between two groups F I G U R E 6 Immunoblot and Immunofluorescence staining reveals increased intrahepatic IL-1 expression in CD68 + macrophages in liver tissue from HIV-infected patients. (A) IL-1 protein in human liver tissues was detected by Western blotting, GAPDH was used as internal control. Representative Western blot shown with densitometry from all specimens (P = 0.02) ((normal (n = 10) and HIV-1 monoinfected (n = 7)). (B) Confocal microscopic analysis of IL-1 and CD68 co-immunostaining in normal (n = 10) and HIV-1-infected liver tissues (n = 7). CD68 + liver macrophages (red), IL-1 (green) and nucleus (blue). (C) Colocalization analysis reveals increased co-localization of IL-1 and CD68 using image J in HIV-1 patients' liver tissues compared to normal healthy livers (P = 0.0001). Increased IL-1 fluorescent intensity (= total intensity × Person's R value) in HIV-1 liver tissue compared to normal livers (P < 0.0001). (D) Confocal microscopic analysis of IL-1 , NLRP3 and CD68 co-immunostaining in HIV-1-infected liver tissues. CD68 + liver macrophages (red), IL-1 (green), NLRP3 (magenta), and nucleus (blue). Panel A: Paired t test; Panel C: Welch's test donors and HIV-1 + patients were purified and examined by Western blotting. As shown in Fig. 6A, a high expression of IL-1 was detected in HIV-1 + human liver tissues. To examine cellular localization, the liver tissues were co-immunostained for CD68 and IL-1 . HIV livers demonstrated an increased expression of IL-1 compared to normal livers with a high degree of colocalization in CD68 + macrophages (Fig. 6B and C). Furthermore, in higher power views, IL-1 and NLRP3 are colocalized (Fig. 6D) . Consistent with previous data, these results further support the role of the IL-1 response of CD68+ liver macrophages in HIV-infected patients.
DISCUSSION
Overall our results suggest that HIV infection of CD68 + liver macrophages results in an amplified IL-1 response to LPS that is mediated through the TLR4-NLRP3 pathway. These findings are supported both ex vivo/in vitro HIV-1 BaL infection of primary human liver macrophages and in vivo data derived from the livers of HIV-infected patients.
Macrophages are considered a major contributor to HIV-1 transmission and persistent infection. 24 Although macrophages are not dividing cells, a high level of HIV-1 replication has been detected in the cells and well documented in a variety of studies. 25, 26 In the liver, KCs Innate immune responses with inflammasome activation plays a critical role in the progression of chronic liver disease and may be partially related to increases in gut permeability and microbial translocation into the portal vein, which delivers proinflammatory bacterial products to the liver. 10 Fibrosis progression in HIVinfected patients is accelerated in patients with liver disease across a range of etiologies despite ART, and may also be associated with microbial translocation. 34 The liver is an immunologically complex organ and serves as the gatekeeper for gut-derived pathogens/PAMPS to prevent them from promoting systemic immune activation. Dozens of DAMPS, including ATP, are constantly released from activated intrahepatic immune cells and injured parenchymal or nonparenchymal cells. Both PAMPS and DAMPS can result in high and persistent IL-1 inflammatory responses in liver macrophages. 35 It has been shown that HIV-1 can infect resident hepatic macrophages both in vitro and in vivo.
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